By Katherine Hamilton
PepGen shares fell after the company shared mixed results for its muscle-disorder treatment.
The stock slid 48% to $2.20 in after-hours trading Monday. Shares are down 35% this year.
PepGen shared results of a trial of patients with myotonic dystrophy type 1, a disorder that causes muscle weakness. The trial measured improvements in restoring normal RNA splicing in muscle tissue among patients.
Patients taking 5 mg/kg of PGN-EDODM1 showed a mean splicing correction of 7.3%, just above the 6.8% in placebo-treated patients, PepGen said.
The mean splicing correction rate among treated patients was weighed down by one patient, who had a worsening in splicing correction while taking the drug. The patient showed 70.8% worsening in splicing correction, dragging the group's average splicing correction down from 22.9%.
No meaningful improvements were observed in a 10-meter walk/run test or in handgrip strength.
PepGen does believe the total safety and efficacy results support the potential of the ongoing trial of patients taking 10 mg/kg. Clinical results for that trial are expected in the second half of 2026.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 30, 2026 18:09 ET (22:09 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.